Genomind's Industry Accolades Expand, Bolstered By A Strong Scientific Advisory Board

KING OF PRUSSIA, Pa., June 5, 2017 /PRNewswire/ -- Genomind, a personalized medicine company bringing innovation to mental healthcare through genetic testing, continues to benefit from the knowledge of an esteemed and respected Scientific Advisory Board (SAB). This board, whose members are thought leaders in the study and understanding of issues ranging from Alzheimer's to ADHD, serves as a strong foundation for the company's commitment to excellence. This commitment has recently been recognized with a trio of additional honors.

The 2017 American Business Awards awarded Genomind a "Golden Stevie" as the "Most Innovative Company of the Year" in the "up to 100 employees" category. The award is to "honor and generate public recognition of the achievements and positive contributions of organizations and working professionals worldwide."

For the second year in a row, Modern Healthcare named Genomind to its "Best Places to Work in Healthcare" list, which "honors workplaces throughout the healthcare industry that empower employees to provide patients and customers with the best possible care, products and services."

In addition, MedReps.com has named the company its "Top Biotech Companies to Work For - Best of 2017" in the "best small biotech" category. The website reported that a "strong product line and commitment to research and development were the top two qualities respondents expect from the best biotech companies to work for."

Genomind is grateful for these acknowledgements and is thankful for the guidance of its SAB, which helps keep Genomind continually focused on its goal of partnering with clinicians to improve their patients' lives.

Genomind's SAB members are:

• Scott T. Aaronson, MD, who specializes in treatment-resistant affective disorders and is a Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and the Associate Medical Director and Director of Clinical Research at The Retreat at Sheppard Pratt.
• P. Murali Doraiswamy, MD, a globally recognized expert and researcher focusing on intervention and treatment possibilities for Alzheimer's and other memory disorders and a Professor in the Department of Psychiatry at Duke University Medical Center.
• Stephen Faraone, PhD, an expert in the nature and causes of mental disorders in childhood. In 2005, ISI determined him to be the second highest cited author in the area of ADHD.  He is a Distinguished Professor at the State University of New York Upstate Medical University and serves in various editor roles for medical journals.
• Maurizio Fava, MD, who has been principal investigator of more than 40 National Institute of Mental Health and industry-supported clinical trials in unipolar depression and is Executive Vice Chair of the Department of Psychiatry at the Massachusetts General Hospital.
• Anil Malhotra, MD, whose research focuses on identifying the biological underpinnings of schizophrenia and the mechanism of action of antipsychotic drugs.  He is the Director of Psychiatry research at the Zucker Hillside Hospital, Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine and an investigator at the Feinstein Institute for Medical Research.
• Roy H. Perlis, MD, MSc, whose research is focused on difficult-to-treat or treatment resistant mood disorders, including major depressive disorder and bipolar disorder.  He is the Director of the Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital Department of Psychiatry and a Professor at Harvard Medical School.
• Stephen M. Stahl, MD, PhD, an author of hundreds of articles and more than 1,500 scientific presentations and abstracts; he is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology.  He is Adjunct Professor of Psychiatry at the University of California, San Diego and Honorary Visiting Senior Fellow, University of Cambridge, U.K.  
• Mark A. Stein, PhD, ABPP, who serves as the President of the American Professional Society of ADHD and Related Disorders (APSARD).  He is the Director of PEARL Clinic/ADHD and Related Disorders Program at Seattle Children's Hospital and an investigator at Seattle Children's Research Institute.
• Rudolph E. Tanzi, PhD, a widely respected researcher focusing on the molecular and genetic factors of neurological diseases, with significant interest on Alzheimer's disease.  He is the Director of the Genetics and Aging Research Unit at the Massachusetts General Institute for Neurodegenerative Disease and a Professor of Neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University.

About Genomind

Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients' lives. Learn more at www.genomind.com.

About the Genecept Assay

The Genecept Assay is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com.

MEDIA CONTACTS:

Kristina Habermann
Vice President, Marketing and Corporate Communications
Genomind
267-326-2166
[email protected]

Adam Shapiro
ASPR
202-427-3603
[email protected]

SOURCE Genomind

Related Links

http://www.genomind.com